Enzo's Q4 Revenues Fall, Losses Widen; Company to Recognize $2M From Sigma Settlement in Q1 '07 | GenomeWeb
NEW YORK (GenomeWeb News) - Enzo Biochem on Friday reported an 8.7-percent decline in revenues atop a widened net loss for its fourth fiscal quarter.
 
For the quarter ended July 31, Enzo posted revenues of $9.9 million, down from $10.9 million in the year-ago period.
 
The company’s quarterly net loss more than doubled to $4.5 million from $2 million in the fourth quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.